
Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s mRNA-1010 seasonal influenza vaccine.
As the regulatory agency agreed to review MRNA’s revised application, its stock price rallied past its 20-day moving average (MA), signaling bullish momentum could sustain in the near term.